OncoKB Information

View Top Employees from OncoKB

OncoKB™ is a comprehensive precision oncology knowledge base developed at Memorial Sloan Kettering Cancer Center that annotates the oncogenic effects and clinical actionability of somatic alterations in cancer. OncoKB™ assigns evidence-based levels of clinical actionability to individual mutational events in a tumor type-specific context. As of 2024, OncoKB™ contains annotations for >7500 alterations in >850 cancer-associated genes. In October 2021, OncoKB™ became partially FDA recognized as a public human genetic variant database to support clinical validity for genetic and genomic-based in vitro diagnostics. As of 2024, OncoKB™ has published two articles that outline the precision oncology cancer therapy landscape and detail how OncoKB™ integrates within this landscape: • Suehnholz, et al. Quantifying the Expanding Landscape of Clinical Actionability for Patients with Cancer. Cancer Discovery, 2023. • Chakravarty, et al. OncoKB: A Precision Oncology Knowledge Base. JCO Precision Oncology, 2017. OncoKB™ offers licenses for academic, commercial and hospital use, with which users can programmatically access the web API. Please visit our website for inquiries regarding licenses.

Website	https://www.oncokb.org/
Employees	6 (1 on RocketReach)
Industry	Biotechnology Research
Keywords	Precision Oncology, Cancer Genomics, Molecular Oncology, Oncology Data, Clinical Oncology, Personalized Medicine, Cancer Informatics, Cancer Research, Cancer Treatment, Cancer Genetics, Cancer Biomarkers, Drug Discovery, Cancer Therapies, Clinical Trials
Competitors	Tempus Labs, Inc., Guardant Health, Myriad Genetics, Foundation Medicine, Caris Life Sciences, Invitae, Freenome, Biocept, Inc., Strata Oncology, Talis Biomedical Corporation +41 more (view full list)